Tecartus — Total revenues
Gilead Sciences Tecartus — Total revenues decreased by 17.6% to $75.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $78.00M to $75.00M. Over 3 years (FY 2022 to FY 2025), Tecartus — Total revenues shows an upward trend with a 4.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration and clinical adoption of the therapy, while a decrease may signal increased competition, patent expirations, or shifts in treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the commercialization of a specific cell therapy product lin...
Peer comparison
Comparable to revenue metrics for specialized oncology or rare disease therapies at other biopharmaceutical companies, often evaluated against market share in specific cancer indications.
gild_segment_tecartus_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $74.75M | $74.75M | $74.75M | $74.75M | $92.50M | $92.50M | $92.50M | $92.50M | $100.00M | $107.00M | $98.00M | $98.00M | $78.00M | $92.00M | $83.00M | $91.00M | $75.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +23.7% | +0.0% | +0.0% | +0.0% | +8.1% | +7.0% | -8.4% | +0.0% | -20.4% | +17.9% | -9.8% | +9.6% | -17.6% |
| YoY Change | — | — | — | — | +23.7% | +23.7% | +23.7% | +23.7% | +8.1% | +15.7% | +5.9% | +5.9% | -22.0% | -14.0% | -15.3% | -7.1% | -3.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's tecartus — total revenues?
- Gilead Sciences (GILD) reported tecartus — total revenues of $75.00M in Q1 2026.
- How has Gilead Sciences's tecartus — total revenues changed year-over-year?
- Gilead Sciences's tecartus — total revenues decreased by 3.8% year-over-year, from $78.00M to $75.00M.
- What is the long-term trend for Gilead Sciences's tecartus — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's tecartus — total revenues has grown at a 4.8% compound annual growth rate (CAGR), from $299.00M to $344.00M.
- What does tecartus — total revenues mean?
- The total amount of money earned from sales of the Tecartus cell therapy product.